The effect of beet root juice consumption on blood pressure and endothelial function of Hypertension patients.

The effect of beet root juice consumption on blood pressure and endothelial function (FMD) of Hypertension patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201211109662N5

Enrollment

Registered

2013-01-15

Start date

2011-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Blood pressure. Condition 2: flow-mediated dilatation (FMD). Hypertensive diseases Diseases of arteries, arterioles and capillaries

Interventions

Intervention 1: 250 ml raw beet root juice for 15 days will be consumed. Intervention 2: Group 2: 500 mg cooked beet root for 15 days will be consumed.

Treatment - Drugs

250 ml raw beet root juice for 15 days will be consumed

Group 2: 500 mg cooked beet root for 15 days will be consumed

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: hypertensive patients whit :BMI more than 18 and less than 35kg/m2 ; Systolic blood pressure (SBP) more than 100 and less than 160 mm Hg; Diastolic blood pressure (DBP) more than 50 and less than 100 mm Hg Exclusion criteria: Individuals with a history of diseases; diabetes; cardiovascular disease; liver and kidney as well as those with thyroid disease; pregnant and breastfeeding; metabolic and endocrine diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Positive changes in inflammatory markers. Timepoint: Baseline and after 15 days. Method of measurement: ELISA kit.;Positive changes in endothelial function. Timepoint: Baseline and after 15days. Method of measurement: Doppler ultrasonography.	—

Secondary

Measure	Time frame
Decrease in blood pressure. Timepoint: Baseline and after 15 days. Method of measurement: Sphygmomanometer.;Positive changes in lipid profiles. Timepoint: Baseline and after 15days. Method of measurement: kit.;Cholesterol Level. Timepoint: Before and after15days. Method of measurement: kit.;HDL Level. Timepoint: Before and after15days. Method of measurement: kit.;LDL level. Timepoint: Before and after15days. Method of measurement: kit.;FBS level. Timepoint: Before and after15days. Method of measurement: kit.;Nitrat level. Timepoint: Before and after 15days. Method of measurement: kit.;Nitrit Level. Timepoint: Before and after 15days. Method of measurement: kit.;Nitritoxidas level. Timepoint: Before and after 15days. Method of measurement: kit.;Antioxidant capacity. Timepoint: Before and after15days. Method of measurement: kit.	—

Measure

Time frame

Decrease in blood pressure. Timepoint: Baseline and after 15 days. Method of measurement: Sphygmomanometer.;Positive changes in lipid profiles. Timepoint: Baseline and after 15days. Method of measurement: kit.;Cholesterol Level. Timepoint: Before and after15days. Method of measurement: kit.;HDL Level. Timepoint: Before and after15days. Method of measurement: kit.;LDL level. Timepoint: Before and after15days. Method of measurement: kit.;FBS level. Timepoint: Before and after15days. Method of measurement: kit.;Nitrat level. Timepoint: Before and after 15days. Method of measurement: kit.;Nitrit Level. Timepoint: Before and after 15days. Method of measurement: kit.;Nitritoxidas level. Timepoint: Before and after 15days. Method of measurement: kit.;Antioxidant capacity. Timepoint: Before and after15days. Method of measurement: kit.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026